Alicia Marie Heidenreich, MD | |
2500 Metrohealth Dr, Cleveland, OH 44109-1900 | |
(216) 778-4486 | |
Not Available |
Full Name | Alicia Marie Heidenreich |
---|---|
Gender | Female |
Speciality | Radiology - Diagnostic Radiology |
Location | 2500 Metrohealth Dr, Cleveland, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083790760 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Alicia Marie Heidenreich, MD 2500 Metrohealth Dr, Cleveland, OH 44109-1900 Ph: (216) 778-4486 | Alicia Marie Heidenreich, MD 2500 Metrohealth Dr, Cleveland, OH 44109-1900 Ph: (216) 778-4486 |
News Archive
The American Medical Group Association (AMGA) today announced 19 leading medical groups and organized systems of care that will be participating in its ACO Development Collaborative, scheduled to have its first meeting in conjunction with the AMGA National Summit on Accountable Care Organizations (ACOs). These organizations represent more than 10,500 providers serving approximately 5 million patients in the United States.
According to an Access Economics study commissioned by the Alzheimer's Australia the number of Victorian dementia patients will quadruple in the next 40 years. At present the figures stand at 66,000 and are expected to touch 246,000 in 2050. The rise is an alarming 275% and is fueled by population growth, reduced physical activity, and an increasingly ageing population. Alzheimer's Australia warns Victorian Health authorities to start planning for measures to curb the epidemic.
Why do some people experience a "placebo effect" that makes them feel better when they receive a sham treatment they believe to be real — while other people don't respond at all to the same thing, or even feel worse?
Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of The Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs, which include cyclo-oxygenase-2 inhibitors (coxibs).
My wife and I attended my 30-year college reunion a couple of weekends ago, but the partying was bittersweet. My freshman roommate, Scott Androes, was in a Seattle hospital bed, a victim in part of a broken health care system. Strip away the sound and fury of campaign ads and rival spinmeisters, and what's at stake in this presidential election is, in part, lives like Scott's. ... Scott now, at age 52, is suffering from Stage 4 prostate cancer, in part because he didn't have health insurance.
› Verified 5 days ago